Literature DB >> 21295855

Specific killing of CCR9 high-expressing acute T lymphocytic leukemia cells by CCL25 fused with PE38 toxin.

Yi Hu1, Li Zhang, Ranran Wu, Rongfei Han, Yanhan Jia, Zhengming Jiang, Mengxin Cheng, Jing Gan, Xiang Tao, Qiuping Zhang.   

Abstract

We have previously demonstrated that CCR9 plays a pivotal role in drug resistance and invasion in human acute T-lymphocytic leukemia (T-ALL). In this study, we investigated whether the MOLT4 cells, which naturally express CCR9 at high levels, can be successfully killed by the specific ligand, CCL25 fused to Pseudomonas exotoxin 38 (PE38) toxin. Our results demonstrated that CCL25-PE38 was able to specifically kill MOLT4 cells via apoptosis induction, and suppress the growth of CCR9(+) tumors. This work shows that CCR9 high-expressing human T-ALL cells can be successfully killed by delivering PE38 toxin fused to the ligand CCL25.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21295855     DOI: 10.1016/j.leukres.2011.01.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.715


  9 in total

1.  CCL25 Signaling in the Tumor Microenvironment.

Authors:  Hina Mir; Shailesh Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  CCR9 in cancer: oncogenic role and therapeutic targeting.

Authors:  Zhenbo Tu; Ruijing Xiao; Jie Xiong; Kingsley M Tembo; Xinzhou Deng; Meng Xiong; Pan Liu; Meng Wang; Qiuping Zhang
Journal:  J Hematol Oncol       Date:  2016-02-16       Impact factor: 17.388

3.  Novel peptide screened from a phage display library antagonizes the activity of CC chemokine receptor 9.

Authors:  Yi Hu; Aiping Ma; Shan Lin; Yang Yang; Guolin Hong
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

4.  92R Monoclonal Antibody Inhibits Human CCR9+ Leukemia Cells Growth in NSG Mice Xenografts.

Authors:  Beatriz Somovilla-Crespo; Maria Teresa Martín Monzón; Maria Vela; Isabel Corraliza-Gorjón; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

5.  CCR9 Promotes Migration and Invasion of Lung Adenocarcinoma Cancer Stem Cells.

Authors:  Lin Lu; Huan Du; Haowei Huang; Chenxi Wang; Peipei Wang; Zhiqiang Zha; Yong Wu; Xia Liu; Chengyin Weng; Xisheng Fang; Baoxiu Li; Haibo Mao; Lina Wang; Mingmei Guan; Guolong Liu
Journal:  Int J Med Sci       Date:  2020-03-26       Impact factor: 3.738

Review 6.  Targeting chemokines for acute lymphoblastic leukemia therapy.

Authors:  Zixi Hong; Zimeng Wei; Tian Xie; Lin Fu; Jiaxing Sun; Fuling Zhou; Muhammad Jamal; Qiuping Zhang; Liang Shao
Journal:  J Hematol Oncol       Date:  2021-03-20       Impact factor: 17.388

7.  TIPE polarity proteins are required for mucosal deployment of T lymphocytes and mucosal defense against bacterial infection.

Authors:  Mingyue Li; Mayassa J Bou-Dargham; Jiyeon Yu; Zienab Etwebi; Honghong Sun; Youhai H Chen
Journal:  Mol Biomed       Date:  2021-12-23

8.  Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts.

Authors:  Sonia Chamorro; Maria Vela; Ana Franco-Villanueva; Laura Carramolino; Julio Gutiérrez; Lucio Gómez; María Lozano; Beatriz Salvador; Mónica García-Gallo; Carlos Martínez-A; Leonor Kremer
Journal:  MAbs       Date:  2014-05-07       Impact factor: 5.857

Review 9.  The role of chemokine receptor 9/chemokine ligand 25 signaling: From immune cells to cancer cells.

Authors:  Cong Wang; Zhenghuan Liu; Zhihui Xu; Xian Wu; Dongyang Zhang; Ziqi Zhang; Jianqin Wei
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.